Also known as diffuse midline glioma (DMG), Matt was struck by the lack of scientific knowledge regarding the pathophysiology of the disease, and by the stark absence of treatments for DIPG patients - so he set about creating his own program of DIPG research. A member of the Australian & New Zealand Children’s Haematology/Oncology Group (ANZCHOG) and the Australian Leukaemia and Lymphoma Group (ALLG), Matt’s latest collaboration with local investigators (Verrills, Enjeti, Lee) tests a new therapy for acute myeloid leukaemia (AML), and aims to identify the influences of the epigenome of the clonal evolution of AM both awarded NHMRC Ideas Grant funding from 2020.Īlthough initially focused on blood cancers, Matt’s research faced an unexpected shift in focus in 2018, when his then 2-year-old daughter Josephine, was diagnosed with Grade IV diffuse intrinsic pontine glioma (DIPG). This profiling strategy attempts to identify novel treatment targets and drug combinations to improve survival. The group employ sophisticated phosphoproteomic techniques to characterise the cellular signalling pathways dysregulated by the genetics individualities of a patient’s cancer.
Recently bestowed as the NSW Premier’s Award for Outstanding Cancer Research Fellow of 2019, Dr Matt Dun guides the CSRG team of staff and students in fields of leukaemic, colonic, and brain cancer research. This was facilitated (and later enhanced) via his securement of successive Cancer Institute NSW Early Career Fellowships (2014-2016, 2017-2019), NHMRC Investigator Grant (2020-2025), Defeat DIPG Chadtough New Investigator Grant (2020-2021) and successful Cancer Institute NSW and NHMRC Equipment Grants to establish a high-resolution mass spectrometry platform at the UON. With his research vision strongly aligned with the University of Newcastle’s Priority Research Centre for Cancer Research, Innovation and Translation (PRC CARiT), Matt formed the Cancer Signalling Research Group (CSRG) based at the University of Newcastle (UON). International post-doctoral training (2013/2014) with field-leading experts in phosphoproteomics (Prof Larsen at SDU) and leukaemia signalling (Prof Cools at KU Leuven), set Matt on a path to establishing his own research laboratory. Soon after, he refocused his research from reproductive cell biology and biochemistry, to the fields of medical biochemistry, cancer cell biology and his now specialty - proteomics and intermolecular interactions. His position and research has been supported by state and/or national funding bodies continuously since 2012, as well as supplemented by philanthropic and industry contributors throughout.ĭecorated by more than 20 national and international awards, Matt achieved his PhD at The University of Newcastle and Hunter Medical Research Institute by publication in 2012. He is currently Senior Lecturer at the University of Newcastle, Australia. DR MATT DUN - BIOMEDICAL SCIENTIST AND 'DIPG DAD'ĭr Matt Dun is a National Health and Medical Research Council (NHMRC) Emerging Leadership Fellow (2020-2024) and a Defeat DIPG Chadtough New Investigator (2020-2021).
0 kommentar(er)
